Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

November 30, 2010

Conditions
Premenstrual Syndrome
Interventions
DRUG

Skin test panel

"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~ Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"

DRUG

Skin test panel

"Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~ Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"

Trial Locations (1)

52621

RECRUITING

Sheba Medical Center, Tel-Hashomer, Ramat Efal

Sponsors
All Listed Sponsors
lead

EVE Medical Systems Ltd.

INDUSTRY